Alzheimer's Archives

News and Trends 12 Jan 2023

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Silo Pharma looks into the 2023 psychedelics crystal ball

Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […]

January 11, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Lifesciences and biotech in 2023

A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […]

January 11, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

2023 Editorial Calendar updated

Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s

Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic test from the Norwegian university hospital AHUS. The company said it will pursue cost-efficient product development with […]

December 22, 2022 - 1 minutemin - By Jim Cornall

News and Trends 30 Nov 2022

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […]

November 30, 2022 - 6 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

Ulrich dauer vivoryon alzheimers disease

Interview 23 Nov 2022

What recent mixed clinical results can teach about Alzheimer’s disease

2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […]

November 23, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2022

Study shows enhanced drug delivery to the brain

In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

More News! 10 Oct 2022

Positive data indicates likely therapeutic effect of Alzheimer’s drug

Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […]

October 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Oct 2022

Japanese scientists find way to detect characteristic of Alzheimer’s disease from blood samples

Researchers from Hokkaido University in Japan and Toppan have developed a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s disease, from biomarkers in blood samples. Alzheimer’s disease is a neurodegenerative disease, characterized by a gradual loss of neurons and synapses in the brain. One of the primary causes of […]

October 7, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us